Renal osteodystrophy in CKD is treated with which combination?

• A. Calcitriol and phosphate binders
• B. Calcium supplements only
• C. Vitamin D2 only
• D. Potassium binders

Answer: (A)

CKD disrupts mineral metabolism, leading to phosphate retention, reduced active vitamin D (calcitriol), low calcium, and secondary hyperparathyroidism that drives renal osteodystrophy. The best approach is to address both phosphate load and vitamin D–dependent signaling. Calcitriol provides the active form of vitamin D, improving calcium absorption and directly suppressing parathyroid hormone. Phosphate binders reduce intestinal phosphate absorption, lowering phosphate excess that fuels PTH elevation. Together, they tackle the two main problems behind CKD-related bone disease: high phosphate and inadequate active vitamin D/PTH balance. Calcium supplements alone don’t adequately control phosphate or PTH and can raise calcium and vascular calcification risk; Vitamin D2 requires renal activation and may be less effective with advanced CKD; potassium binders don’t impact bone-mineral metabolism.